In recent years, patent enforcement between operating companies has been overshadowed by non-practicing entity litigation. The Patent Trial and Appeal Board (PTAB) loomed large as a ...
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback